Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by Hormozgan University of Medical Sciences.
Recruitment status was  Not yet recruiting
Information provided by:
Hormozgan University of Medical Sciences Identifier:
First received: February 6, 2007
Last updated: May 31, 2007
Last verified: February 2007
Hypothesis (H0): Labor duration and obstetric complications are not significantly different in the three groups (misoprostol-dinoprostone-oxytocin).

Condition Intervention Phase
Fetal Death
Fetal Membranes, Premature Rupture
Drug: misoprostol
Drug: dinoprostone
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hormozgan University of Medical Sciences:


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Female

Inclusion Criteria:

  • Term pregnancy
  • Singleton
  • Vertex
  • Bishop score below 6

Exclusion Criteria:

  • History of drug reaction
  • Medical disease
  • IUGR
  • Oligohydramnios
  • Vaginal bleeding
  • Fetal anomaly
  • Uterine scar
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00432588

Iran, Islamic Republic of
Shariaty Maternity Hospital Not yet recruiting
Tehran, Iran, Islamic Republic of
Contact: Mitra Ahmad Soltani, MD    0098 021 22301004   
Sponsors and Collaborators
Hormozgan University of Medical Sciences
Principal Investigator: Mitra Ahmad Soltani Hormozgan University of Medical Sciences
Study Chair: Minoo Rajaee Lari, Perinatologist - Obs and Gyn Department of Obs and Gyn - HUMS
  More Information

Additional Information: Identifier: NCT00432588     History of Changes
Other Study ID Numbers: Misoprostol vs Dinoprostone 
Study First Received: February 6, 2007
Last Updated: May 31, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Hormozgan University of Medical Sciences:

Additional relevant MeSH terms:
Fetal Membranes, Premature Rupture
Fetal Death
Hypertension, Pregnancy-Induced
Pregnancy Complications
Wounds and Injuries
Obstetric Labor Complications
Pathologic Processes
Reproductive Control Agents
Physiological Effects of Drugs
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Anti-Ulcer Agents
Gastrointestinal Agents processed this record on October 27, 2016